GGrantIndex
← Leaderboards

Brian T Fisher

Duke University

$7,185,446
Attributed
$13,574,237
Total exposure
5
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.1M · FY201425
$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$15,501,815 · 6

By mechanism

R01$12,777,582 · 3
U54$2,724,233 · 3

Top collaborators

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Childhood

Research focus

ChildhoodProspectiveChildFoundationsInfectionMorbidity - Disease RateSiteFundingAntifungal TherapyBloodInternationalMortalityEarly DiagnosisMultidisciplinaryGuidelinesCommunicable DiseasesFutureDesignPatient-Focused OutcomesUnited States National Institutes Of HealthAdultResearch PersonnelMoldsBenefits And Risks

Grant awards (24)

Pediatric Fungal Network STudy of Rare Invasive Fungal DisEases in Immunocompromised Pediatric Patients (PFN-STRIDE)$1,927,578
U54 · FY2025 · AI · contact PI
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial$1,223,727
R01 · FY2025 · AI
Pediatric Fungal Network's (PFN) STudy of Rare Invasive Fungal DisEases in Immunocompromised Pediatric Patients (STRIDE) Project 1$614,447
U54 · FY2025 · AI · contact PI
Pediatric Fungal Network's (PFN) STudy of Rare Invasive Fungal DisEases in Immunocompromised Pediatric Patients (STRIDE) Administrative Component$182,208
U54 · FY2025 · AI · contact PI
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial$28,350
R01 · FY2025 · AI
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial$28,350
R01 · FY2025 · AI
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial$28,350
R01 · FY2025 · AI
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial$28,350
R01 · FY2025 · AI
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial$28,350
R01 · FY2025 · AI
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial$28,350
R01 · FY2025 · AI
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial$1,383,097
R01 · FY2024 · AI
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial$1,394,565
R01 · FY2023 · AI
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial$1,468,578
R01 · FY2022 · AI
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections$703,340
R01 · FY2022 · AI
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections$472,708
R01 · FY2021 · AI
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections$305,715
R01 · FY2021 · AI
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections$787,070
R01 · FY2020 · AI
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections$798,798
R01 · FY2019 · AI
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections$820,854
R01 · FY2018 · AI
Fungal biomarkers for diagnosis and response to therapy for pediatric candidemia$631,470
R01 · FY2018 · HD
Fungal biomarkers for diagnosis and response to therapy for pediatric candidemia$640,677
R01 · FY2017 · HD
Fungal biomarkers for diagnosis and response to therapy for pediatric candidemia$642,589
R01 · FY2016 · HD
Fungal biomarkers for diagnosis and response to therapy for pediatric candidemia$642,649
R01 · FY2015 · HD
Fungal biomarkers for diagnosis and response to therapy for pediatric candidemia$691,645
R01 · FY2014 · HD